Tor C Savidge1, Wei-Hua Pan, Paul Newman, Michael O'brien, Pauline M Anton, Charalabos Pothoulakis. 1. Developmental Gastroenterology Laboratory, Combined Program in Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital and Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA. savidge@helix.mgh.harvard.edu
Abstract
BACKGROUND & AIMS: Clostridium difficile causes antibiotic-associated diarrhea and pseudomembranous colitis, diseases afflicting millions of people each year. Although C. difficile releases 2 structurally similar exotoxins, toxin A and toxin B, animal experiments suggest that only toxin A mediates diarrhea and enterocolitis. However, toxin A-negative/toxin B-positive strains of C. difficile recently were isolated from patients with antibiotic-associated diarrhea and colitis, indicating that toxin B also may be pathogenic in humans. METHODS: Here we used subcutaneously transplanted human intestinal xenografts in immunodeficient mice to generate a chimeric animal model for C. difficile toxin-induced pathology of human intestine. RESULTS: We found that intraluminal toxin B, like equivalent concentrations of toxin A, induced intestinal epithelial cell damage, increased mucosal permeability, stimulated interleukin (IL)-8 synthesis, and caused an acute inflammatory response characterized by neutrophil recruitment and tissue damage. Laser capture microdissection and real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) showed that intestinal epithelial cell-specific IL-8 gene expression also was increased significantly after luminal exposure to C. difficile toxins in vivo. CONCLUSIONS: We conclude that C. difficile toxin B, like toxin A, is a potent inflammatory enterotoxin for human intestine. Future therapeutic or vaccine strategies for C. difficile infection therefore need to target both toxins.
BACKGROUND & AIMS:Clostridium difficile causes antibiotic-associated diarrhea and pseudomembranous colitis, diseases afflicting millions of people each year. Although C. difficile releases 2 structurally similar exotoxins, toxin A and toxin B, animal experiments suggest that only toxin A mediates diarrhea and enterocolitis. However, toxin A-negative/toxin B-positive strains of C. difficile recently were isolated from patients with antibiotic-associated diarrhea and colitis, indicating that toxin B also may be pathogenic in humans. METHODS: Here we used subcutaneously transplanted human intestinal xenografts in immunodeficientmice to generate a chimeric animal model for C. difficile toxin-induced pathology of human intestine. RESULTS: We found that intraluminal toxin B, like equivalent concentrations of toxin A, induced intestinal epithelial cell damage, increased mucosal permeability, stimulated interleukin (IL)-8 synthesis, and caused an acute inflammatory response characterized by neutrophil recruitment and tissue damage. Laser capture microdissection and real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) showed that intestinal epithelial cell-specific IL-8 gene expression also was increased significantly after luminal exposure to C. difficile toxins in vivo. CONCLUSIONS: We conclude that C. difficile toxin B, like toxin A, is a potent inflammatory enterotoxin for human intestine. Future therapeutic or vaccine strategies for C. difficileinfection therefore need to target both toxins.
Authors: Rory N Pruitt; Nicole M Chumbler; Stacey A Rutherford; Melissa A Farrow; David B Friedman; Ben Spiller; D Borden Lacy Journal: J Biol Chem Date: 2012-01-20 Impact factor: 5.157
Authors: Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys Journal: Clin Vaccine Immunol Date: 2013-01-16
Authors: Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191